Merrimack shuts down development of investigational cancer drug, staff cuts to follow
April 8, 2019Research and Development, Sales and Marketing cacner, merrimack, oncology, pharma
Merrimack Pharmaceuticals has taken the decision to terminate development of its antibody-directed nanotherapeutic cancer therapy MM-310 in the treatment of …
Top Ten most popular articles on Pharmafile.com this week!
April 5, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, Northern Ireland, Novartis, Placebo, UK, brexit, pharma
As Brexit looms, pharma trade lobby the ABPI called for a ban on exports of medicines in the case of …
FDA approves Pfizer’s Ibrance for advanced male breast cancer
April 5, 2019Medical Communications, Sales and Marketing Cancer, FDA, Pfizer, breast cancer, ibrance, male breast cancer, pharma
The FDA has chosen to expand the indications of Pfizer’s Ibrance (palbociclib), the company announced, approving the CDK4/6 inhibitor in …
BMS Opdivo/Yervoy recommended for untreated kidney cancer via Cancer Drugs Fund
April 5, 2019Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, Kidney cancer, NICE, UK, Yervoy, opdivo
NICE has revealed it is recommending that Bristol-Myers Squibb’s Opdivo (nivolumab), in combination with Yervoy (ipilimumab), be made available to …
Sacklers file motion to throw lawsuit out of court
April 5, 2019Medical Communications Massachusetts, OxyContin, Purdue Pharma, opioid crisis, opioids, sackler
Members of the Sackler family have asked a judge to throw a lawsuit – filed by Massachusetts attorney general Maura …
Memorial Sloan Kettering Cancer Center officials violated conflict of interest policies
April 5, 2019Medical Communications, Research and Development Cancer, Memorial Sloan Kettering Cancer Center, oncology, research
Top officials at the Memorial Sloan Kettering Cancer Center repeatedly violated policies on financial conflicts of interest, according to details …
Crescendo Biologics selects current CFO Theodora Harold as new CEO
April 4, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Cambridge, Crescendo Biologics, Dr Peter Pack, Theo Harold, cfo
Cambridge, UK-based Crescendo Biologics have said current Chief Financial Officer (CFO) Theodora Harold will take over from Dr Peter Pack …
AstraZeneca’s early-stage Fasenra study smashes primary endpoint in hypereosinophilic syndrome
April 4, 2019Research and Development AstraZeneca, Fasenra, hypereosinophilic syndrome, pharma
AstraZeneca has revealed new data for Fasenra (benralizumab), demonstrating that patients using the drug can “achieve near-complete depletion of eosinophils …
NHS England threatened legal action against Oxford University hospitals trust
April 4, 2019Medical Communications, Research and Development Hopsitals, NHS, NHS England, OUH, cancer screening, patients
NHS England threatened to sue Oxford University hospitals (OUH) NHS trust after they objected to the former’s controversial decision to …
Sorrento Therapeutics seek $1 billion from billionaire biotech investor Patrick Soon-Shiong
April 4, 2019Business Services, Sales and Marketing Abraxane, Celgene, Cynviloq, Patrick Soon-Shiong, Sorrento, lawsuits
Sorrento Therapeutics is seeking $1 billion in damages from billionaire biotech investor Patrick Soon-Shiong, owner of US newspaper the LA …
European approval for Pfizer’s Vizimpro in first-line non-small cell lung cancer
April 4, 2019Sales and Marketing Cancer, Europe, Pfizer, Vizimpro, lung cancer, non small cell lung cancer, non-small cell lung cancer, pharma
The European Commission has awarded marketing approval to Pfizer’s tyrosine kinase inhibitor (TKI) Vizimpro (dacomitinib), it has emerged, as a …
HPV vaccine prevents 90% of cervical pre-cancer cases in Scotland, research shows
April 4, 2019Research and Development HPV, Scotland, cervical cancer, immunity, vaccines, virus
Routine vaccination of girls in Scotland against HPV has led to a dramatic drop in cases of cervical cancer, according …
Sangamo and Pfizer’s gene therapy increases FVIII activity in severe haemophilia A in early study
April 3, 2019Research and Development, Sales and Marketing Pfizer, Sangamo, haemophilia, pharma
Sangamo Therapeutics and Pfizer have unveiled new Phase 1/2 data for their jointly developed investigational gene therapy SB-525, demonstrating that …
Children born in poverty show major differences in brain function, study shows
April 3, 2019Research and Development India, UEA, brain development, brain function, childhood, children
Children born into poverty show major differences in early brain function, according to research from the University of East Anglia. …
Clovis Oncology’s Rubraca shows promise in multiple pancreatic tumour mutations, interim data show
April 3, 2019Research and Development Cancer, Clovis Oncology, Pancreatic cancer, Rubraca, oncology, pharma
At the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Clovis Oncology took the opportunity to present …
Janssen closes plant in California, 49 positions axed
April 3, 2019Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, Vacaville, california
Janssen are letting go of 49 employees due to the closure of their plant in Vacaville, California. The Johnson & …
NHS gender pay gap has increased since last year
April 3, 2019Research and Development NHS, NHS trusts, analysis, gender pay gap, salary
The gender pay gap has worsened in the NHS, according to analysis from The Guardian, which found the gender pay …
Novartis’ Cosentyx approved in China for plaque psoriasis
April 2, 2019Manufacturing and Production, Sales and Marketing China, Cosentyx, Novartis, pharma, psoriasis
Novartis has revealed that its interleukin-17A (IL-17A) Cosentyx (secukinumab) has been authorised for use in China in the treatment of …
NICE recommends Eli Lilly’s Verzenio in combination with Fulvestrant for breast cancer
April 2, 2019Manufacturing and Production CDF, Cancer, NICE, breast cancer, britain, oncology
Britain’s cost effectiveness body, the National Institute for Health and Care Excellence (NICE), has recommended Eli Lilly’s Verzenio (abemaciclib) in …
Teva’s Ajovy injection secures EU approval for the prevention of migraine
April 2, 2019Manufacturing and Production, Sales and Marketing EU, Europe, Teva, ajovy, migraine, pharma
Teva has announced that its calcitonin gene-related peptide (CGRP) inhibitor Ajovy (fremanezumab) has been awarded marketing authorisation by the European …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
